Skip to main content

Breakthrough Bleeding

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Birth control pillsN/A1 trial
Active Trials
NCT00120913Completed160Est. Aug 2004
Teva
TevaIsrael - Petach Tikva
1 program
DR-1031PHASE_21 trial
Active Trials
NCT00394771Completed567Est. Mar 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaDR-1031
Oregon TherapeuticsBirth control pills

Clinical Trials (2)

Total enrollment: 727 patients across 2 trials

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Start: Oct 2006Est. completion: Mar 2008567 patients
Phase 2Completed

Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?

Est. completion: Aug 2004160 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.